Evidence map›Paper›PMID 30291648›Full record

ArticleJournal of magnetic resonance imaging : JMRI2019

Evaluation of Effects of TGF-β1 Inhibition on Gastric Cancer in Nude Mice by Diffusion Kurtosis Imaging and In-Line X-ray Phase Contrast Imaging With Sequential Histology.

Bowen Shi, Fei Yuan, Fuhua Yan, Huan Zhang, Zilai Pan, Weibo Chen, Guilong Wang, Jingwen Tan, Yang Zhang, Yuqi Ren and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of magnetic resonance imaging : JMRI, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

Bowen ShiDepartment of Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P.R. China.ORCID 0000-0002-5059-9547
Fei YuanDepartment of Pathology, RuiJin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P.R. China.
Fuhua YanDepartment of Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P.R. China.
Huan ZhangDepartment of Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P.R. China.
Zilai PanDepartment of Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P.R. China.
Weibo ChenPhilips Healthcare, Shanghai, P.R. China.
Guilong WangPhilips Healthcare, Shanghai, P.R. China.
Jingwen TanDepartment of Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P.R. China.
Yang ZhangDepartment of Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P.R. China.
Yuqi RenShanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai, P.R. China.
Lianjun DuDepartment of Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P.R. China.
Shanghai Jiao Tong University · CNPhilips (Finland) · FIChinese Academy of Sciences · CN

Funding

National Natural Science Foundation of China 81771789National Natural Science Foundation of China U1532107
6 · The paper itself

Abstract

backgroundAccurate and complete response evaluation after treatment is important to implement individualized therapy for gastric cancer. PURPOSE: To investigate the effectiveness of diffusion kurtosis imaging (DKI) and in-line X-ray phase contrast imaging (ILXPCI) in the assessment of the therapeutic efficacy by transforming growth factor beta 1 (TGF-β1) inhibition. STUDY TYPE: Prospective animal study. ANIMAL MODEL: Thirty nude mice subcutaneous xenotransplantation tumor model of gastric cancer for DKI and 10 peritoneal metastasis nude mice model for ILXPCI. FIELD STRENGTH/SEQUENCE: Examinations before and serially at 7, 14, 21, and 28 days after TGF-β1 inhibition treatment were performed at 3T MRI including T ASSESSMENT: DKI parameters (apparent diffusion coefficient [ADC], diffusivity [D] and kurtosis [K]) were calculated by two experienced radiologists after postprocessing. STATISTICAL TESTS: For the differences in all the parameters between the baseline and each timepoint for both the treated and the control mice, the Mann-Whitney test was used. The Spearman correlation test was used to evaluate correlations among the DKI parameters and corresponding pathologic necrosis fraction (NF).

resultsADC, D, and K values were significantly different between the two groups after treatment (P < 0.05). Serial measurements in the treated group showed that the ADC, D, and K values were significantly different at 7, 14, 21, and 28 days compared with baseline (P < 0.05). There were significant correlations between DKI parameters and NF (ADC, r = 0.865, P < 0.001; D, r = 0.802, P < 0.001; K, r = -0.944, P < 0.001). The ILXPCI results in the treated group showed a stronger absorption area than the control group. DATA

conclusionDKI may be used to evaluate the complete course therapeutic effects of gastric cancer induced by TGF-β1 inhibition, and the ILXPCI technique will improve the tumor microstructure resolution. LEVEL OF EVIDENCE: 1 Technical Efficacy: Stage 4 J. Magn. Reson. Imaging 2019;49:1553-1564.

Indexed as

AnimalsContrast MediaImage Processing, Computer-AssistedMagnetic Resonance ImagingMaleMiceMice, NudeNeoplasm MetastasisNeoplasm TransplantationPeritoneal NeoplasmsStomach NeoplasmsTransforming Growth Factor beta1X-RaysContrast MediaTgfb1 protein, mouseTransforming Growth Factor beta1DKIgastric cancerILXPCITGF-β1 inhibitiontherapeutic evaluation

Identifiers

PMID30291648
PMCPMC6585615
OpenAlexW2894709795

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.